Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
American Association for the Study of Liver Diseases (AASLD)
Biotech
CymaBay tees up new phase 3 study for resurrected liver drug
CymaBay is getting its liver disease drug back on track with positive data out of a phase 3 study it cut short last year.
Amirah Al Idrus
Nov 16, 2020 8:04pm
Glympse Bio clears first-in-human study of injectable biosensors
Nov 16, 2020 10:49am
AASLD: VBI details hep B candidate as it preps 2020 filing
Nov 12, 2019 9:01am
AASLD: Gilead wants to move the needle for fatty liver therapies
Nov 11, 2019 8:35am
